首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1903790

全球MYC標靶療法市場：市場機會、標靶策略、技術開發平台及臨床試驗展望（2026年）

Global MYC Targeting Therapies Market Opportunity, Targeting Approaches, Technology Development Platforms & Clinical Trials Insight 2026

出版日期: 2026年01月01日 | 出版商:

KuicK Research | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球MYC標靶療法市場 - 市場機會、標靶策略、技術開發平台及臨床試驗展望（2026年） - 發現與亮點

預計首個MYC標靶療法將於2030年前獲批
全球MYC標靶療法市場機會展望
MYC標靶療法臨床試驗的全面洞察：超過10種療法
按公司、國家、適應症和階段劃分的MYC標靶藥物臨床試驗洞察
依公司劃分的MYC標靶療法開發平台：超過5種標靶平台
MYC標靶療法臨床試驗的啟動日期和預計完成日期適應症
競爭格局

MYC標靶療法的需求及本報告的意義

MYC標靶療法的科學和商業格局正從概念探索階段過渡到具有可量化早期進展的結構化開發項目。隨著越來越多的公司尋求將MYC生物學轉化為實用的治療方法，決策者需要超越科學複雜性的清晰可靠的資訊。本報告旨在滿足此需求。

MYC仍然是癌症生物學中最重要的致癌驅動因子之一，它影響多種腫瘤類型的細胞增殖、代謝、壓力反應和存活機制。由於MYC是許多致癌路徑的核心，因此能夠安全改變其活性的療法有望得到廣泛的臨床應用。然而，這項機會也伴隨著技術挑戰。 MYC深度整合於調控網絡中，具有高度動態性，且結構複雜。因此，隨著該領域的發展勢頭強勁，需要專門的報告來幫助利害關係人了解不斷變化的競爭格局，解讀企業所採取的科學策略，並為合作和投資做好準備。

本報告提供策略視角，涵蓋最相關的數據，包括研發管線、合作夥伴關係、技術平台、地理佈局、臨床策略和競爭優勢，旨在幫助企業儘早進入這個未來幾年有望顯著增長的市場。

本報告包含臨床試驗洞察

本報告系統而詳細地概述了處於臨床前和臨床開發階段的候選MYC靶向化合物。雖然目前處於人體試驗階段的化合物數量仍然很高，但相關活動正在增加，計畫也正進入更成熟的階段。試驗遍及美國、歐洲、中國和澳洲等主要地區，涵蓋了MYC擴增、過度表現或路徑依賴性尤為突出的多種適應症。

本報告深入探討了開發人員如何應對調控主調控因子所固有的高風險，包括治療環境、分子模式、生物標記策略和試驗設計的考量。此外，報告還介紹了在推進早期轉化研究方面發揮關鍵作用的機構贊助商、學術合作者和技術授權者。由於 MYC 生物學具有高度的背景依賴性，這些試驗層面的細節可以幫助利害關係人評估哪些方法在臨床上最一致且在商業上最可行。

透過將分散的試驗資訊整合到一個統一的結構中，本報告有助於更深入地了解全球 MYC 標靶治療領域的成熟度、進展速度和潛在的轉折點。

參與 MYC 標靶治療研發的主要公司

目前，這個充滿活力的領域得到了成熟創新者和新興生技公司的共同支持。儘管目前已採用多種策略，包括直接抑制劑、降解促進劑、轉錄調節劑以及基於RNA/寡核苷酸的技術，但其共同目標是在最大限度降低毒性的同時，精準抑制MYC活性。

根據這份報告，開發結構導向抑制劑、MYC/MAX破壞劑、標靶蛋白降解劑、合成致死策略以及用於細胞內轉錄因子的下一代遞送平台的公司，對市場的影響最大。這些公司正在迅速建立合作夥伴關係，以加速技術轉移、確保平台技術的安全性並開發概念驗證資料集。

由於該領域仍處於早期階段，投資者、合作夥伴和競爭對手需要了解哪些公司擁有深厚的科學實力、可擴展的平台以及差異化的戰略地位。

本報告涵蓋的技術平台

本報告的一個關鍵章節重點介紹了支持MYC標靶藥物開發的底層技術。一個特別值得關注的平台是快速發展的以蛋白質為中心和以結構為導向的治療模式。這些模式旨在靶向固有無序蛋白（IDP），包括MYC。傳統藥物設計一直難以有效標靶IDP。

例如，先進的勝肽模擬系統和標靶降解技術已展現出在破壞MYC複合物穩定性、改變其構象狀態以及調節蛋白質在DNA上的滯留方面的巨大潛力。這為開發能夠直接與MYC相互作用的藥物奠定了基礎，而不僅僅依賴通路層面的調控。

透過系統地梳理這些技術組成部分，本報告清楚地闡明了推動研發管線成長和競爭差異化的技術引擎。

一份描繪MYC標靶治療領域未來發展方向的報告

隨著MYC標靶治療的不斷深入，該領域應朝著精準的患者分層、多樣化的治療模式、聯合治療策略以及更深入的生物學圖譜構建方向發展。儘管MYC標靶療法尚未商業化，但首次人體臨床試驗的早期成功以及不斷增長的投資正在重塑未來十年的格局。

本報告概述了影響市場成熟度的發展趨勢、合作機會和科學轉折點。隨著MYC標靶療法穩步邁向臨床和商業化應用，本報告提供了一個前瞻性的分析框架，幫助利害關係人駕馭這一複雜但快速發展的治療領域，從而掌握其發展歷程中的關鍵時刻。

First MYC Targeting Therapy Approval Expected By 2030
Global MYC Targeting Therapies Market Opportunity Outlook
Comprehensive Insight On MYC Targeting Therapies In Clinical Trials: > 10 Therapies
MYC Targeting Drugs Clinical Trials Insight By Company, Country, Indication & Phase
MYC Targeting Therapies Development Platforms By Companies: > 5 Targeting Platforms
MYC Targeting Therapies Clinical Studies Start & Expected Completion Timeline By Indication
Competitive Landscape

MYC Targeted Therapies Need & Why This Report?

Concept exploration is giving way to structured development programs with quantifiable early stage progress in the scientific and commercial landscape for MYC targeted therapies. Decision makers need clear, reliable information that cuts through scientific complexity as more companies try to convert MYC biology into practical therapeutic approaches. The purpose of this report is to address that need.

With effects on cellular proliferation, metabolism, stress response, and survival mechanisms across a variety of tumor types, MYC continues to be one of the most important oncogenic drivers in cancer biology. Since MYC is at the core of numerous oncogenic circuits, any treatment that can safely alter its activity may have a wide range of clinical applications. However, this opportunity is accompanied by technical challenges: MYC is deeply ingrained in regulatory networks, highly dynamic, and structurally elusive. Therefore, at a time when the field is gaining momentum, a specialized report is necessary to assist stakeholders in comprehending the developing competitive environment, interpreting the scientific strategies companies are pursuing, and positioning themselves for partnership or investment.

This report provides a strategic lens for companies looking to get involved early in a market that is anticipated to grow significantly over the coming years by compiling the most pertinent data on pipelines, partnerships, technology platforms, geographic footprints, clinical strategies, and competitive differentiation.

Clinical Trials Insight Included In Report

The report offers a structured and detailed overview of MYC targeted candidates that progress through preclinical and clinical development. Despite the number of compounds that remain in human trials, activity is picking up; likewise, programs are now entering more mature stages. The trials span major global regions such as the United States, Europe, China, and Australia; indications also vary in which MYC amplification, overexpression, or pathway dependency is particularly prominent.

Insights include the therapeutic setting, molecular modality, biomarker strategy, and study design considerations in short, how developers are meeting the inherently high risks of modulating a master regulator. The report further provides insight into the institutional sponsors, academic collaborators, and technology licensors that have been instrumental in driving early translation. Given the highly context dependent nature of MYC biology, these trial level details will help stakeholders assess which approaches are most clinically coherent and commercially viable.

This report allows for further understanding of developmental maturity, pace of progression, and potential inflection points across the global MYC targeting landscape by consolidating dispersed trial information in a unified structure.

Leading Companies Engaged In R&D Of MYC Targeted Therapies

These days, this dynamic field is supported by both established innovators and a growing base of up-and-coming biotech's. Although different strategies have been used, such as direct inhibitors, degraders, transcriptional modulators, and RNA- or oligo based technologies, the common goal is to precisely reduce MYC activity while minimizing toxicity.

The development of structure guided inhibitors, MYC/MAX disruptors, targeted protein degraders, synthetic-lethal methods, and next generation delivery platforms appropriate for intracellular transcription factors are among the companies most actively influencing the market, according to this report. These organizations are working fast to establish partnerships to speed up translation, secure enabling technologies, and develop proof-of-concept datasets.

The investors, partners, and competitors need to understand which companies possess scientific depth, scalable platforms, or differentiated strategic positions at this very nascent stage of the space.

Technology Platforms Included In Report

A key section of the report focuses on enabling technologies that support MYC directed drug development. Among these platforms highlighted is the rapidly emerging class of protein-centric and structure-guided modalities engineered to engage intrinsically disordered proteins-IDPs-a category into which MYC falls and that historically has resisted traditional drug design.

Advanced peptidomimetic systems and targeted degradation technologies, for instance, are showing promising potential in the destabilization of MYC complexes, shifting conformational states, or modulating protein residency on DNA. This provides a platform for developing agents that may be able to engage with MYC in a direct manner, as opposed to relying on pathway level modulation alone.

By cataloging these, the report brings clarity on the technology engines that power pipeline growth and shape competitive differentiation.

Report Indicating Future Direction Of MYC Targeted Therapies Segment

The field should increasingly move towards precise patient stratification, diversified therapeutic modalities, combination strategies, and more-in-depth biological mapping as the targeting of MYC continues to advance. While no MYC targeted therapy has gone through commercialization yet, early successes coming from first-in-human trials and an upward ramping investment are reworking expectations for the decade to come.

The report outlines the developmental trajectories, partnership opportunities, and scientific inflection points emerging to influence the market maturation. It provides a forward-looking analytical framework that will enable stakeholders to navigate a complex but rapidly strengthening therapeutic area-capturing a timely moment of evolution as MYC focused interventions steadily move closer to clinical and commercial reality.

1. Research Methodology

2. Introduction To MYC

2.1 Overview Of MYC In Cancer
2.2 MYC As Therapeutic Target In Oncology

3. MYC: Structure, Evolution, & Role In Cancer

3.1 Structure & Function Of MYC Proteins
3.2 Historical Discovery & Evolution Of MYC As Cancer Target
3.3 Mechanisms Of MYC Dysregulation In Tumorigenesis
3.4 MYC Driven Pathways In Cancer Development

4. Therapeutic Approaches To MYC Targeting

4.1 Direct vs. Indirect MYC Targeting
- 4.1.1 Direct MYC Targeting
- 4.1.2 Indirect MYC Targeting
4.2 Approaches For MYC Targeting
- 4.2.1 Small Molecule Inhibitors
- 4.2.2 Oligonucleotide Based Therapies
- 4.2.3 Targeted Protein Degradation

5. Global MYC Targeting Therapies Clinical Trials Overview

5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Phase

6. Global MYC Targeting Drugs Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II

7. MYC Targeting Therapies Development Platforms By Companies

8. MYC Targeting Therapies Development Trends By Indication

8.1 Hematologic Malignancies
8.2 Solid Tumors
8.3 Potential Expansion Into Non-Cancer Indications

9. Global MYC Targeting Therapy Market Scenario

9.1 Current Market Overview
9.2 Future Market Opportunities

10. Global MYC Targeting Therapy Market Dynamics

10.1 Market Drivers & Opportunities
10.2 Market Challenges & Solutions

11. Competitive Landscape

11.1 Genetic Leap
11.2 Curigin
11.3 IDP Pharma
11.4 Incurix
11.5 Omega Therapeutics
11.6 Panavance Therapeutics
11.7 Peptomyc
11.8 Suzhou Kintor Pharmaceuticals
11.9 Wayfinder Biosciences
11.10 WebenPharma

簡介目錄圖表

List of Figures

Figure 2-1: Dual Identity Of MYC In Normal vs. Cancer Cells
Figure 2-2: Challenge Of Drugging MYC
Figure 2-3: Cancer - Upstream Routes That Activate MYC
Figure 2-4: From Barriers To Breakthroughs In MYC
Figure 2-5: Blood Cancers: Ideal Early MYC Targets
Figure 3-1: MYC Family Members - Key Biology
Figure 3-2: Regulatory Roles Of The MYC Box Motifs
Figure 3-3: Expanded Roles Of The Structured C-Terminus Beyond MAX Binding
Figure 3-4: What Makes MYC So Potent
Figure 3-5: MYC Research Evolution
Figure 3-6: Milestones In MYC Discovery & Targeting
Figure 3-7: How Multiple Mechanisms Affect MYC
Figure 3-8: Signaling Pathways Leading To MYC Activation
Figure 3-9: Converging Forces Leading To MYC Driven Malignancy
Figure 3-10: MYC Driven Proliferation & Cell Cycle Control
Figure 3-11: Interconnected Metabolic Effects Of MYC
Figure 3-12: MYC As Central Oncogenic Hub
Figure 4-1: Direct MYC Targeting

Figure 4-2 Indirect MYC Targeting

Figure 4-3: MYC Targeted Small Molecules
Figure 4-4: MYC Targeted Oligonucleotides
Figure 4-5: MYC Targeted Protein Degradation
Figure 5-1: Global - MYC Targeting Therapies Clinical Trials By Company, 2026
Figure 5-2: Global - MYC Targeting Therapies Clinical Trials By Country, 2026
Figure 5-3: Global - MYC Targeting Therapies Clinical Trials By Indication, 2026
Figure 5-4: Global - Number of MYC Targeting Therapies In Clinical Trials By Phase, 2026
Figure 7-1: The Genetic Leap AI stack
Figure 7-2: Transcription Factor-Targeted Drug Discovery Platform - Incurix
Figure 7-3: Bi-specific siRNA - Curigin
Figure 8-1: Hematological Cancer - Regulation Of MYC
Figure 8-2: Solid Tumors - Mechanisms Of MYC Deregulation
Figure 8-3: Solid Tumors - MYC Driven Cellular Programs
Figure 8-4: OMO-103-02 Phase I (NCT06059001) Study - Initiation & Completion Year
Figure 8-5: VHIO23003 Phase 2 (NCT06650514) Study - Initiation & Completion Year
Figure 8-6: GP-2250-1001 Phase I (NCT03854110) Study - Initiation & Completion Year
Figure 8-7: MYC as a Central Regulator in Non-Oncologic Diseases
Figure 9-1: Global MYC Targeting Therapy Market - Future Opportunities
Figure 10-1: Global MYC Targeting Therapy Market - Drivers & Opportunities
Figure 10-2: Global MYC Targeting Therapy Market - Challenges & Solutions